Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
Sponsor: Mandana Kamgar, MD
Summary
This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based treatment strategies and the feasibility of administering MEKi combination therapies to patients with KRAS G12R mutated advanced pancreatic ductal adenocarcinoma (PDAC).
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
80
Start Date
2023-02-07
Completion Date
2027-08-01
Last Updated
2025-04-24
Healthy Volunteers
No
Conditions
Interventions
combination therapy with no MEKi
This cohort will receive combination therapy with no MEKi.
combination therapy with MEKi-HCQ
This cohort will receive combination therapy with MEKi-HCQ.
combination therapy with MEKi-EGFRi
This cohort will receive combination therapy with MEKi-EGFRi.
combination therapy with MEKi.
This cohort will receive combination therapy with MEKi.
Locations (1)
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States